Aura Biosciences, Inc.

Stage 3 · Topping · week 4

As of Oct 22, 2026, Aura Biosciences is in Stage 3, the topping phase, now in week 4 (since Sep 28, 2026). It closed at $6.46, 27.4% below its 52-week high and below its 200-day average, which is rising.

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. More about the company

$6.46

+0.00% today

$670M · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is AURA early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S4 18w

S4 21w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 5w → S4 15w → S1 2w → S4 4w → S1 4w → S4 18w → S1 3w → S2 9w → S3 1w → S2 7w → S3 7w → S4 21w → S1 13w → S4 12w → S1 3w → S4 10w → S1 4w → S2 11w → S3 6w → S2 5w → S3 4w current

Total tracked: 165 weeks across 22 stage runs.

AURA among Biotechnology167th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…167	AURAAura Biosciences, Inc.	Stage 3 · wk 4	59	+7.3%

vs 52W High

-27.4%

$4.97 lo$8.90 hi

27.4% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 4

1w13w26w

Week 4, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-3.3%

200 DMA: $6.68 · rising

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

1.02x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+7.3%

-8.4%

-11.0%

YTD

+21.9%

+5.6%

Scan Membership

Breakout Watch

Latest: 2024-10-22

3 appearances in last 60 days. First seen: 2023-07-11.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 4 · Vol 1.02x

2026-10-21S3

Wk 4 · Vol 0.85x

2026-10-20S3

Wk 4 · Vol 1.26x

2026-10-19S3

Wk 4 · Vol 0.60x

2026-10-16S3

Wk 3 · Vol 0.83x

2026-10-15S3

Wk 3 · Vol 0.66x

2026-10-14S3

Wk 3 · Vol 1.12x

2026-10-13S3

Wk 3 · Vol 1.90x

2026-10-12S3

Wk 3 · Vol 0.71x

2026-10-09S3

Wk 2 · Vol 1.12x

2026-10-08S3

Wk 2 · Vol 2.03x

2026-10-07S3

Wk 2 · Vol 0.88x

Moving averages & range

50 DMA

$6.86

200 DMA

$6.68

52W High

$8.90

52W Low

$4.97

5D Low

$6.10

Resistance levels (recent highs)

20d High

$6.56

60d High

$8.16

120d High

$8.90

250d High

$8.90

Next resistance

+1.5%

to 20d High

ROE

-53.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.1

Aura Biosciences: quick answers

What stage is Aura Biosciences in?

As of Oct 22, 2026, Aura Biosciences (AURA) is in Stage 3, the topping phase. It entered Stage 3 on Sep 28, 2026 and is in week 4. What the four stages mean

Is Aura Biosciences in an uptrend?

Its uptrend has stalled. Aura Biosciences is in Stage 3, the topping phase that follows an advance. It trades 3.3% below its 200-day average, which is rising.

How far is Aura Biosciences from its 52-week high?

Aura Biosciences closed at $6.46 on Oct 22, 2026, 27.4% below its 52-week high of $8.90. Its 52-week low is $4.97.

How has Aura Biosciences performed over the past year?

As of Oct 22, 2026, Aura Biosciences is up 5.6% over the past year and up 21.9% so far in 2026.

Which sector and industry is Aura Biosciences in?

Aura Biosciences is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.